Press Release Archive

November 17, 2011 - Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program

(BUSINESS WIRE)--Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center’s Corporate Citizenship Award in the Best International Ambassador category for Pfizer’s Global Health Partnerships program. The “Citizens” Awards honor excellence in corporate citizenship and civic leadership for initiatives in both the United States and across the world. “The essence of a successful corporate social

November 16, 2011 - Pfizer’s Vyndaqel® (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)

(BUSINESS WIRE)--Pfizer announced today that the European Commission has approved Vyndaqel® (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. TTR-FAP is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide. 1,2,3 “A diagnosis of TTR-FAP, usually made in patients during their mid-

November 16, 2011 - The Advil® Congestion Relief Project Hits the Road to Relieve Congestion in Communities

(BUSINESS WIRE)--Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, yesterday, kicked off a nationwide effort to make a difference in communities. The cold and flu brand is putting a twist on its tagline – “The Right Relief for the Real Problem,” and providing literal relief in congested places across the US. In its first relief stop, The Advil® Congestion Relief Project unveiled a new library at P.S. 130 in the Bronx.

November 14, 2011 - Kathryn Joosten Speaks Out About Lung Cancer Profiles; ‘Desperate’ to Share Her Personal Lung Cancer Story to Help Others

(BUSINESS WIRE)--Kathryn Joosten, two-time Emmy® Award-winning actress and star of Desperate Housewives and The West Wing, is opening up about her 10-year battle with lung cancer as part of a new national campaign, Lung Cancer Profiles. Lung Cancer Profiles aims to reduce the stigma associated with lung cancer by educating about the diversity of the disease inside and out. The campaign, created by Pfizer Oncology in collaboration with the

November 12, 2011 - New Data Presented On Phase 3 Trial Of ELIQUIS® (apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical Illness

(BUSINESS WIRE)--PRINCETON, N.J.

November 7, 2011 - Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency. The study met its primary endpoint, as treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urinary urgency episodes overnight

November 7, 2011 - Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd Annual Meeting Of The American Society Of Hematology

(BUSINESS WIRE)--Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML),1 inotuzumab in non-Hodgkin lymphoma (NHL),2 as well as the first presentation of clinical data for PF-04449913,3 which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.4 In addition, ongoing investigator-initiated research on gemtuzumab

November 5, 2011 - Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients with Moderately Active Disease

(BUSINESS WIRE)--THOUSAND OAKS, Calif.

October 31, 2011 - Pfizer Reports Third-Quarter 2011 Results

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter(4) Year-to-Date(4) 2011 2010 Change

October 27, 2011 - Pfizer Completes Acquisition Of Icagen

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer. Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6.00 in cash, without interest thereon, and

October 27, 2011 - Pfizer Declares A 20-Cent Fourth-Quarter 2011 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent fourth-quarter 2011 dividend on the company’s common stock, payable December 6, 2011, to shareholders of record at the close of business on November 11, 2011. The fourth-quarter 2011 cash dividend will be the 292nd consecutive quarterly dividend paid by Pfizer.

October 26, 2011 - Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has established a research collaboration with Medco Health Solutions, Inc. (NYSE: MHS) and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes. The collaboration is intended to enhance Pfizer’s precision medicine approach, which

October 26, 2011 - Pfizer Establishes Precision Medicine Research Collaboration With Medco

October 25, 2011 - Peggy Fleming and the Makers of Robitussin® Provide Relief this Cold and Flu Season with a Simple Question: "Does Your Last Name Sound Contagious?"

(BUSINESS WIRE)--This week, Robitussin® marked the start of another cold and flu season by shaking up the most contagious months of the calendar year for America’s “sick but can’t stop” sufferers with the launch of the Simple Acts of Relief program. To kick-off the launch of the program, Robitussin® has teamed up with iconic Olympic and World ice skating champion and sports commentator, Peggy Fleming. As the “simplest” act of relief, the

October 25, 2011 - Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search

(BUSINESS WIRE)--The World Intellectual Property Organization (WIPO), in an unprecedented collaboration with leading pharmaceutical companies and BIO Ventures for Global Health (BVGH), launched today WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat

October 24, 2011 - Pfizer Invites Public to View and Listen to Webcast of November 6 Pfizer Analyst and Investor Meeting at ACR

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s specialty care leadership team at an analyst and investor meeting on Sunday, November 6, 2011 at 6:30 p.m. Central Standard Time, in connection with the annual meeting of the American College of Rheumatology (ACR). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “

October 20, 2011 - Additional Data From Pfizer’s Prevnar 13® Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of America

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional data from several clinical studies of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), which is being held Oct. 20-23, 2011, in Boston, Mass. The data from these studies provide support for the

October 17, 2011 - Pfizer Animal Health and the Resource Foundation Expand Initiative to Increase Productivity of Small Family Farms in Latin America and India

(BUSINESS WIRE)--Pfizer Animal Health and The Resource Foundation announced today the expansion of a comprehensive education and training program to increase the capacity, productivity and quality of life of rural farmers in eight Latin American countries. Plans call for tailoring the program to the needs of rural communities in India. The agreement was guided by results of a decade-long collaboration also announced today. Pfizer

October 13, 2011 - Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for Seniors

((BUSINESS WIRE)--LOUISVILLE, Ky

October 5, 2011 - Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor

(BUSINESS WIRE)--Pfizer Inc. announced today an agreement with Puma Biotechnology, Inc. for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, being studied for the treatment of cancer. Under the terms of the agreement, Puma will assume sole responsibility for global development and commercialization of neratinib. Pfizer

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.